GlassScriptPhysician profile
Luke Talbot Brown
NPI 1780295725
$3,083.98
in general payments reported to CMS, 2019-2025
35 companies · $398 in 2025
The $398 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $303 · 2023: $1,815 · 2024: $567 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,780.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $436.41 | 2022-2025 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $363.65 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $242.66 | 2022-2025 | Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.10 | 2023-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $198.52 | 2023-2024 | Rexulti, Nuedexta |
| Glaxosmithkline, LLC. | $159.11 | 2023 | Trelegy Ellipta, Shingrix |
| Myriad Women'S Health, INC. | $152.86 | 2023 | Myrisk |
| Daiichi Sankyo INC. | $151.47 | 2022-2024 | Injectafer |
| Mylan Specialty L.P. | $130.65 | 2022-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $100.78 | 2022-2023 | |
| Novo Nordisk INC | $89.94 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Radius Health, INC. | $55.66 | 2023-2025 | Tymlos |
| Lundbeck LLC | $53.80 | 2022-2023 | Rexulti |
| Phathom Pharmaceuticals, INC. | $53.48 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $50.03 | 2023-2024 | Xarelto |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $49.76 | 2023-2024 | |
| Eisai INC. | $44.46 | 2024-2025 | |
| Insulet Corporation | $44.40 | 2022-2024 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.27 | 2022-2023 | Synjardy |
| Exact Sciences Corporation | $39.99 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $39.71 | 2023 | |
| International Rehabilitative Sciences, INC | $37.96 | 2025 | Rs-4i Plus With Intersperse |
| Astellas Pharma US INC | $36.58 | 2023-2025 | Veozah |
| Nestle Healthcare Nutrition INC. | $35.66 | 2022-2023 | |
| Dexcom, INC. | $34.60 | 2023-2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $33.24 | 2023 | Trintellix |
| Amgen INC. | $33.10 | 2023-2025 | Repatha, Otezla, Evenity |
| Scilex Pharmaceuticals INC. | $31.09 | 2022-2023 | Ztlido |
| Aimmune Therapeutics, INC. | $29.96 | 2024 | |
| Novartis Pharmaceuticals Corporation | $22.51 | 2022 | |
| Xeris Pharmaceuticals, INC. | $21.66 | 2024 | Gvoke Hypopen |
| Vyaire Medical, INC. | $19.79 | 2023 | |
| Halozyme INC | $17.26 | 2023 | |
| Acella Pharmaceuticals, LLC | $16.43 | 2025 | NP Thyroid 60 |
| Ultragenyx Pharmaceutical INC. | $13.43 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.